Abstract
There have been several recent reports of the development of acquired hemophilia in patients who received alemtuzumab treatment for multiple sclerosis.[1] [2] [3] [4] [5] [6] [7] This monoclonal antibody is increasingly noted to be associated with secondary autoimmune disorders since its approval for use in multiple sclerosis a decade ago.[8] Common autoimmune disorders developing after alemtuzumab therapy are thyroid diseases and immune thrombocytopenia (ITP).[8] With the addition of acquired hemophilia to this list, it may be useful to examine whether this unusual complication may shed some light on the pathogenesis of acquired hemophilia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
